Graphite Bio Inc GRPH:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 09/30/22 EDT
3.17UNCH (UNCH)
Volume
597
Close
3.17quote price arrow up+0.10 (+3.26%)
Volume
104,073
52 week range
2.07 - 17.10
Loading...
  • Open3.06
  • Day High3.33
  • Day Low3.04
  • Prev Close3.07
  • 52 Week High17.10
  • 52 Week High Date10/01/21
  • 52 Week Low2.07
  • 52 Week Low Date05/25/22

Key Stats

  • Market Cap183.76M
  • Shares Out57.97M
  • 10 Day Average Volume0.19M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-74.5

KEY STATS

  • Open3.06
  • Day High3.33
  • Day Low3.04
  • Prev Close3.07
  • 52 Week High17.10
  • 52 Week High Date10/01/21
  • 52 Week Low2.07
  • 52 Week Low Date05/25/22
  • Market Cap183.76M
  • Shares Out57.97M
  • 10 Day Average Volume0.19M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-74.5

RATIOS/PROFITABILITY

  • EPS (TTM)-1.58
  • P/E (TTM)-2.00
  • Fwd P/E (NTM)-1.59
  • EBITDA (TTM)-84.706M
  • ROE (TTM)-23.77%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Graphite Bio Inc

 

Content From Our Affiliates

Profile

MORE
Graphite Bio, Inc. is a clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. Its gene-editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The Company's lead product candidate, GPH101, is a differentiated approach with the potential to directly correct the mutation that causes...
Perry Karsen
Independent Chairman of the Board
Joshua Lehrergraiwer M.D.
President, Chief Executive Officer, Director
Alethia Young
Chief Financial Officer
Address
201 Haskins Way, Suite 210
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
RAIN
Rain Therapeutics Inc
4.88-0.75-13.32%
CTXR
Citius Pharmaceuticals Inc
1.21-0.05-3.97%
ATNM
Actinium Pharmaceuticals Inc
7.37+0.17+2.29%
VSTM
Verastem Inc
0.85-0.0171-1.9721%
CLNN
Clene Inc.
2.80-0.01-0.36%